Compare · BIAF vs PPD
BIAF vs PPD
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- PPD is the larger of the two at $16.64B, about 3642.3x BIAF ($4.6M).
- BIAF has hit the wire 20 times in the past 4 weeks while PPD has been quiet.
- PPD has more recent analyst coverage (1 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- PPD, Inc.
- Price
- $3.70-7.50%
- $47.29-0.07%
- Market cap
- $4.6M
- $16.64B
- 1M return
- -58.66%
- -
- 1Y return
- -92.75%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2020
- News (4w)
- 20
- 0
- Recent ratings
- 0
- 1
PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Latest BIAF
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- SEC Form PRER14A filed by bioAffinity Technologies Inc.
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form 424B5 filed by bioAffinity Technologies Inc.
- bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form 424B5 filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Latest PPD
- InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
- Saama Appoints Scott Rogers as Company's Chief Financial Officer
- SEC Form 15-12B filed by PPD, Inc.
- SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)
- SEC Form SC 13G filed by PPD, Inc.
- SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company
- SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company
- SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company